Manufacturing, Biologics

Aragen Bioscience has licensed ProteoNic Biotechnology’s 2G UNic recombinant protein production technology, which increases manufacturing efficiency and reduces cost of goods for recombinant biologicals.

New single-use technologies and other filtration systems are beginning to address cost, throughput, and manufacturing footprint demands.

Biopharmaceutical company BeiGene plans to build facility in Suzhou to expand its clinical capability and prepare for commercial manufacturing.

Licenses could potentially bring antibody R&D to areas beyond oncology, such as diabetes treatments

GEA's self-contained homogenizer is designed for laboratory applications, including cell dispersions.

A thorough cell-bank testing plan is necessary to certify the safety and purity of a resulting biopharmaceutical product.

The Mobius 2000-L single-use bioreactor from EMD Millipore offers configurable software, hardware, and single-use Flexware assemblies for suspension and adherent cell-culture applications.

Catalent licenses Excelimmune’s antibody combination therapy platform toenable the manufacture of multiple recombinant antibodies in a single batch culture.

Biogen plans to build a biologics manufacturing plant in northwest Switzerland using next-generation technologies to create efficiency and sustainability.

GSK will invest in an additional downstream isolation facility for amoxicillin production in Singapore.

Australian company, Genea Biocells, will open a facility in San Diego, California for cell and culture-media manufacturing and R&D.

IDT Biologika acquired Aeras' vaccine manufacturing facility, and the companies will work together on tuberculosis vaccine development.

Novasep's new antibody drug conjugate facility at its site in Le Mans, France will be commissioned in 2016.

Automation and disposables continue to reduce human error.

Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.

Medicago's new production facility will make plant-based vaccines and therapeutics.

Choosing the optimal protein expression vector depends on strain, promoter, and a number of other factors.

This article presents first-hand perspectives from industry users to suppliers of single-use sensors.

Making the switch from batch to continuous manufacturing requires a thorough understanding of the process.

It is important to understand degradation and processing to maintain product stability in biologics.

Antibodies in research should be standardized and categorized using a barcode-like classification system, according to research published in Nature.

They may not be glamorous, but buffers play an important role in biopharma manufacturing.

The use of commercially available media to achieve high titer in early process development is discussed.

Under terms of the agreement, Zymeworks could earn up to $164 million per successful drug candidate.

Catalent announced that it would partner with Mitsubishi Gas Chemical Company, and its subsidiary MGC Pharma, to promote GPEx technology, a high-titer vector for stable mammalian cell lines.

Sanofi will tap into Boehringer Ingelheim’s therapeutic monoclonal antibody manufacturing capabilities.

Single-use components aid efficiency in automated personalized therapy manufacturing.

Improving efficiency, value chain, quality, and protein complexity with advanced bioprocess development.

The partnership will focus on the discovery of antibodies against proteins that are not easily purified in functional form.

Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.